Literature DB >> 24794489

Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients.

Lourdes Mateo1, Susana Holgado2, Maria Luisa Mariñoso3, Ricard Pérez-Andrés4, Anna Bonjoch5,6, Joan Romeu6, Alejandro Olivé2.   

Abstract

Tenofovir disoproxil fumarate (TDF) is an adenine analogue reverse transcription inhibitor widely used in first-line treatment of human immunodeficiency virus (HIV) infection and also in hepatitis B virus infection. Its use has been linked to sporadic Fanconi syndrome, renal failure and bone disease. We present the clinical characteristics of tenofovir-induced osteomalacia, discuss bone biopsy findings, describe predisposing factors and compare our results with other reported cases. We describe five cases of hypophosphatemic osteomalacia induced by TDF and recorded at the rheumatology service of a university hospital between 2010 and 2014. We also report the characteristics of bone biopsies of this pathology, which have not been previously described. We include a review of published cases of proximal renal tubulopathy (PRT) and osteomalacia induced by TDF (PubMed 1995-2014; keywords: osteomalacia, tenofovir, Fanconi syndrome, hypophosphatemic osteomalacia, proximal renal tubulopathy, bone biopsy). Five HIV patients who developed hypophosphatemic osteomalacia under TDF treatment (>5 years) presented increasing bone pain and a progressive inability to walk without assistance as a result of multiple insufficiency fractures. Bone biopsy performed in three patients after tetracycline labelling showed increased osteoid thickness, confirming osteomalacia. A literature review retrieved 17 publications on this condition, including 53 cases: 26 patients developed isolated PRT, 25 presented PRT and with multiple insufficiency fractures and two presented isolated bone disease, including osteomalacia and osteoporosis. Rheumatologists should be alert to this complication in patients receiving tenofovir. The main complaint reported by these patients is diffuse pain, predominantly in the lower limbs, indicating multiple stress fractures. Serum phosphate and appropriate screening for abnormal proximal tubule function should be monitored. Bone scintigraphy should be carried out in cases of limb pain before the occurrence of more severe complications.

Entities:  

Keywords:  Fanconi syndrome; HIV; Hypophosphatemic osteomalacia; Osteomalacia; Proximal renal tubulopathy; Tenofovir

Mesh:

Substances:

Year:  2014        PMID: 24794489     DOI: 10.1007/s10067-014-2627-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  36 in total

1.  Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.

Authors:  Samir K Gupta; Joseph A Eustace; Jonathan A Winston; Ivy I Boydstun; Tejinder S Ahuja; Rudolph A Rodriguez; Karen T Tashima; Michelle Roland; Nora Franceschini; Frank J Palella; Jeffrey L Lennox; Paul E Klotman; Sharon A Nachman; Stephen D Hall; Lynda A Szczech
Journal:  Clin Infect Dis       Date:  2005-04-22       Impact factor: 9.079

2.  [Hypophosphatemia and multiple fractures in patient with human immunodeficiency virus infection treated with tenofovir].

Authors:  Lluís Roselló; Anna Gort; Ramón Planella; Jacint Cabau
Journal:  Med Clin (Barc)       Date:  2007-06-30       Impact factor: 1.725

Review 3.  Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.

Authors:  Anthony E Zimmermann; Thomas Pizzoferrato; John Bedford; Anne Morris; Robert Hoffman; Gregory Braden
Journal:  Clin Infect Dis       Date:  2005-12-08       Impact factor: 9.079

4.  Interactions of HIV protease inhibitors with ATP-dependent drug export proteins.

Authors:  H Gutmann; G Fricker; J Drewe; M Toeroek; D S Miller
Journal:  Mol Pharmacol       Date:  1999-08       Impact factor: 4.436

Review 5.  Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.

Authors:  Andrew M Hall; Bruce M Hendry; Dorothea Nitsch; John O Connolly
Journal:  Am J Kidney Dis       Date:  2011-03-23       Impact factor: 8.860

6.  Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.

Authors:  Hassane Izzedine; Jean Sebastien Hulot; Daniel Vittecoq; Joel E Gallant; Schlomo Staszewski; Vincent Launay-Vacher; Andrew Cheng; Gilbert Deray
Journal:  Nephrol Dial Transplant       Date:  2005-03-01       Impact factor: 5.992

7.  Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.

Authors:  Steven Coca; Mark A Perazella
Journal:  Am J Med Sci       Date:  2002-12       Impact factor: 2.378

8.  Bone scintigraphy and secondary osteomalacia due to nephrotoxicity in a chronic hepatitis B patient treated with tenofovir.

Authors:  M V Gómez Martinez; F G Gallardo; T Pirogova; J García-Samaniego
Journal:  Rev Esp Med Nucl Imagen Mol       Date:  2013-08-04       Impact factor: 1.359

9.  Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.

Authors:  Ei Kinai; Hideji Hanabusa
Journal:  AIDS Res Hum Retroviruses       Date:  2009-04       Impact factor: 2.205

10.  Tenofovir-related Fanconi's syndrome and osteomalacia in a teenager with HIV.

Authors:  Julie M Lucey; Peter Hsu; John B Ziegler
Journal:  BMJ Case Rep       Date:  2013-07-09
View more
  19 in total

Review 1.  Role of Phosphate in Biomineralization.

Authors:  Sanjay Kumar Bhadada; Sudhaker D Rao
Journal:  Calcif Tissue Int       Date:  2020-07-25       Impact factor: 4.333

Review 2.  Endocrinological aspects of HIV infection.

Authors:  F S Mirza; P Luthra; L Chirch
Journal:  J Endocrinol Invest       Date:  2018-01-08       Impact factor: 4.256

3.  Clinical and laboratory features of patients with osteomalacia initially presenting with neurological manifestations.

Authors:  S W Kim; N Hong; Y Rhee; Y-C Choi; H Y Shin; S M Kim
Journal:  Osteoporos Int       Date:  2018-04-05       Impact factor: 4.507

4.  Hypophosphatemia in the setting of metabolic bone disease: case reports and diagnostic algorithm.

Authors:  Alvin Lee Day; Sarah L Morgan; Kenneth G Saag
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-06-15       Impact factor: 5.346

Review 5.  Tenofovir and bone health.

Authors:  Philip M Grant; Aoife G Cotter
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

6.  Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.

Authors:  Sara Jeong; Hyun Phil Shin; Ha Il Kim
Journal:  Intervirology       Date:  2021-11-03       Impact factor: 2.294

Review 7.  The Causes of Hypo- and Hyperphosphatemia in Humans.

Authors:  Eugénie Koumakis; Catherine Cormier; Christian Roux; Karine Briot
Journal:  Calcif Tissue Int       Date:  2020-04-13       Impact factor: 4.333

8.  Molecular Control of Phosphorus Homeostasis and Precision Treatment of Hypophosphatemic Disorders.

Authors:  Thomas J Weber; L Darryl Quarles
Journal:  Curr Mol Biol Rep       Date:  2019-02-09

9.  Effects of renal tubular dysfunction on bone in tenofovir-exposed HIV-positive patients.

Authors:  Lisa Hamzah; Amanda Samarawickrama; Lucy Campbell; Matthew Pope; Keith Burling; Martin Fisher; Yvonne Gilleece; Karen Walker-Bone; Frank A Post
Journal:  AIDS       Date:  2015-09-10       Impact factor: 4.177

10.  Fanconi Syndrome Leading to Hypophosphatemic Osteomalacia Related to Tenofovir Use.

Authors:  Mana Rao; Liam Dadey; Thomas Glowa; Peter Veldkamp
Journal:  Infect Dis Rep       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.